JP2004515460A - ざ瘡によって誘発される炎症および真皮マトリックス分解酵素に対して用いる組成物および方法 - Google Patents

ざ瘡によって誘発される炎症および真皮マトリックス分解酵素に対して用いる組成物および方法 Download PDF

Info

Publication number
JP2004515460A
JP2004515460A JP2001585747A JP2001585747A JP2004515460A JP 2004515460 A JP2004515460 A JP 2004515460A JP 2001585747 A JP2001585747 A JP 2001585747A JP 2001585747 A JP2001585747 A JP 2001585747A JP 2004515460 A JP2004515460 A JP 2004515460A
Authority
JP
Japan
Prior art keywords
inhibitor
acne
skin
composition
elastase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001585747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004515460A5 (enExample
Inventor
ジェイ． ヴォルヒース，ジョン
カング，セウォン
ジェイ． フィッシャー，ゲーリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of JP2004515460A publication Critical patent/JP2004515460A/ja
Publication of JP2004515460A5 publication Critical patent/JP2004515460A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22—Peroxides; Oxygen; Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001585747A 2000-05-22 2001-05-22 ざ瘡によって誘発される炎症および真皮マトリックス分解酵素に対して用いる組成物および方法 Pending JP2004515460A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57659700A 2000-05-22 2000-05-22
US09/852,154 US20040235950A1 (en) 1999-05-20 2001-05-09 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
PCT/US2001/016537 WO2001089502A2 (en) 2000-05-22 2001-05-22 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes

Publications (2)

Publication Number Publication Date
JP2004515460A true JP2004515460A (ja) 2004-05-27
JP2004515460A5 JP2004515460A5 (enExample) 2008-07-10

Family

ID=27076996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001585747A Pending JP2004515460A (ja) 2000-05-22 2001-05-22 ざ瘡によって誘発される炎症および真皮マトリックス分解酵素に対して用いる組成物および方法

Country Status (7)

Country Link
US (2) US20040235950A1 (enExample)
EP (1) EP1284721A2 (enExample)
JP (1) JP2004515460A (enExample)
AU (1) AU2001271266A1 (enExample)
CA (1) CA2409929A1 (enExample)
MX (1) MXPA02011431A (enExample)
WO (1) WO2001089502A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009545604A (ja) * 2006-07-31 2009-12-24 イーエルシー マネージメント エルエルシー ミツガシワ（Ｍｅｎｙａｎｔｈｅｓｔｒｉｆｏｌｉａｔａ）の葉抽出物を含む老化防止組成物とその使用方法
JP2011518214A (ja) * 2008-04-22 2011-06-23 サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィク メラニン形成を阻害するためのＫｉｆ１３Ａ阻害剤およびＡＰ−１阻害剤の使用
WO2023068233A1 (ja) * 2021-10-18 2023-04-27 マルホ株式会社 活性阻害及び／又は産生抑制剤

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050033251A1 (en) * 1998-12-08 2005-02-10 Quick-Med Technologies, Inc. Controlled release of biologically active substances from select substrates
DE10127432A1 (de) * 2001-06-06 2002-12-12 Beiersdorf Ag Wirkstoffkombination zur Verhinderung unerwünschter Hautpigmentierung
US20100222316A1 (en) * 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
EP1971868A2 (en) * 2006-01-05 2008-09-24 Galderma Research & Development, S.N.C. Acne lesions biomarkers and modulators thereof
AU2007299562A1 (en) * 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor
WO2008053199A1 (en) * 2006-10-30 2008-05-08 Astrazeneca Ab Combination therapy for the treatment of respiratory diseases
US10179900B2 (en) * 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
BR112012004834A2 (pt) * 2009-09-02 2018-03-13 Univ Virginia Patent Foundation acompanhar a probabilidade de hipoglicemia iminente em diabetes de dados de automonitiração de glicose no sangue (smbg)
US8895628B2 (en) * 2010-10-25 2014-11-25 Johnson & Johnson Consumer Companies, Inc. Compositions comprising a retinoid and an NFkB-inhibitor and their methods of use
US20140086859A1 (en) 2012-09-24 2014-03-27 Johnson & Johnson Consumer Companies, Inc. Low oil compositions comprising a 4-substituted resorcinol and a high carbon chain ester
RU2015156254A (ru) * 2014-05-07 2017-07-04 Конинклейке Филипс Н.В. Устройство, система и способ выделения физиологической информации
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
KR20200063798A (ko) * 2018-11-28 2020-06-05 박정혜 퀘르세틴, 제니스테인 및 알파리포산을 함유하는 여드름 피부 개선용 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005198A (en) * 1975-09-12 1977-01-25 Robert H. Van Aman Treatment of acne vulgaris
US4219548A (en) * 1978-09-01 1980-08-26 The Procter & Gamble Company Topical anti-inflammatory composition
US4942031A (en) * 1988-02-23 1990-07-17 Levin Robert H Compositions containing LYCD and other topically active medicinal ingredients
LU87410A1 (fr) * 1988-12-20 1990-07-10 Cird Composition cosmetique ou pharmaceutique contenant des microspheres de polymeres ou de corps gras chargees d'au moins un produit actif
JPH07501540A (ja) * 1991-11-25 1995-02-16 リチャードソン、ビックス、インコーポレーテッド 皮膚シワ及び／又は皮膚萎縮を調節するための組成物
DE4218572A1 (de) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
US5460620A (en) * 1992-07-31 1995-10-24 Creative Products Resource, Inc. Method of applying in-tandem applicator pads for transdermal delivery of a therapeutic agent
FR2694934B1 (fr) * 1992-08-24 1994-11-10 Oreal Composition pour le traitement de l'acné contenant un dérivé d'acide salicylique et dérivés d'acide salicylique.
CA2160139A1 (en) * 1993-04-07 1994-10-13 Richard Edward Galardy Synthetic matrix metalloprotease inhibitors and uses thereof
FR2715565B1 (fr) * 1994-01-31 1996-03-15 Oreal Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation.
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
CN1107495C (zh) * 1994-07-01 2003-05-07 纺织研究院公司 去屑组合物
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
DE4444238A1 (de) * 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
US5643623A (en) * 1995-06-07 1997-07-01 Mars Incorporated Health food product and its uses
US6218128B1 (en) * 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
US5741896A (en) * 1996-06-21 1998-04-21 Allergan O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
DE19632840A1 (de) * 1996-08-14 1998-02-19 Landsberger Albert Vitamin A-haltige Zusammensetzung
US5665367A (en) * 1996-09-27 1997-09-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin care compositions containing naringenin and/or quercetin and a retinoid
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
US5962030A (en) * 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
TWI234467B (en) * 1997-06-04 2005-06-21 Univ Michigan Composition for inhibiting photoaging of skin
WO1999009982A1 (en) * 1997-08-25 1999-03-04 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009545604A (ja) * 2006-07-31 2009-12-24 イーエルシー マネージメント エルエルシー ミツガシワ（Ｍｅｎｙａｎｔｈｅｓｔｒｉｆｏｌｉａｔａ）の葉抽出物を含む老化防止組成物とその使用方法
JP2011518214A (ja) * 2008-04-22 2011-06-23 サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィク メラニン形成を阻害するためのＫｉｆ１３Ａ阻害剤およびＡＰ−１阻害剤の使用
WO2023068233A1 (ja) * 2021-10-18 2023-04-27 マルホ株式会社 活性阻害及び／又は産生抑制剤

Also Published As

Publication number Publication date
EP1284721A2 (en) 2003-02-26
CA2409929A1 (en) 2001-11-29
MXPA02011431A (es) 2004-01-26
AU2001271266A1 (en) 2001-12-03
US20040235950A1 (en) 2004-11-25
US20060009494A1 (en) 2006-01-12
WO2001089502A3 (en) 2003-01-03
WO2001089502A2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
US7795302B2 (en) Use of compositions for treating rosacea
Searle et al. The top 10 cosmeceuticals for facial hyperpigmentation
Araviiskaia et al. The role of topical dermocosmetics in acne vulgaris
JP2004515460A (ja) ざ瘡によって誘発される炎症および真皮マトリックス分解酵素に対して用いる組成物および方法
US8784852B2 (en) Topical skin care composition
CN1819824B (zh) 抗氧化剂在皮肤病和/或化妆品组合物中的用途
EP3030229B1 (en) Anti-acne compositions comprising bile acid-fatty acid conjugates
US5922335A (en) Uses for ascorbyl-phosphoryl-cholesterol in topical compositions
US20080070874A1 (en) Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
JP3590369B2 (ja) クリプトタンシノンを含むニキビ予防及び治療用化粧料組成物
JP2004512294A (ja) 加齢の徴候を処置するためのプロビタミンａ活性を有する少なくとも１種のカロチノイドとプロビタミンａ活性を有さない少なくとも１種のカロチノイドの組合せ物の使用
US5730992A (en) Compositions for the treatment of skin disorders
Putriana et al. Recent Advance Bakuchiol Application as a Potential Alternative to Retinol in Skincare and Cosmetics
AU2002340915A1 (en) Use of compositions for treating rosacea
EP1080719A2 (en) Methods for potentiation of efficacy of topical actives by mono-acyl-(lyso)-glycerophosholipids
Herschthal et al. Cutaneous aging: a review of the process and topical therapies
CN103327957B (zh) 亮肤组合物
Devvanshi et al. COSMECEUTICAL: THEIR ROLE AS ANTI-AGING AND THEIR FUTURE ASPECTS
Tedeschi et al. Cosmeceuticals in dermatology
Marciniak et al. The Role of Cannabinoids in the Treatment of Skin Diseases: A Review of Mechanisms of Action and Clinical Evidence
Hira Ghani et al. IN-DEPTH REVIEW
Linder Daily care for acne, hyperpigmentation, aging, and sensitive skin
Merinville 22 Hydroxyacids and Salicylic Acid
Milani et al. Efficacy of a retinoid complex plus anti-inflammatory component cream alone or in combination with prebiotic food supplement in adult acne: A randomized, assessor-blinded, parallel-group, multicentre trial on 184 women.
Kindred et al. COS DERM

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111005